Appears on
Articles319
NHS data infrastructure must support the research needs of the life sciences sector
Co-designing new networks with research users is critical to delivering the full scientific and commercial value of NHS health data.
The government and ABPI agree to accelerate a planned review of VPAG
A planned autumn review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) will be brought forward to report back in June.
ABPI response to Prime Minister's announcement on support for medical research
The Prime Minister has announced new funding and ambitious targets for UK medical research today (7 April).
Russell Abberley confirmed as ABPI President-elect
Russell Abberley, Vice President and General Manager of Amgen UK and Ireland, has been confirmed as ABPI President-elect
ABPI response to DSIT spending allocations
The Department for Science, Innovation and Technology (DSIT) has today announced funding for research and development, including in life sciences.
Delivering the NHS 10-Year Plan will require a fourth ‘shift’ says ABPI
Creating an NHS fit for the future will mean investing in innovative medicines and vaccines to transform people’s lives.
UK set to demand a third of pharmaceutical company revenue in second half of 2025
The government is proposing to raise the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject companies' NHS sales in the second half of 2025.
Industry/academia links fuel UK medical innovation
As National Apprenticeship Week (10 - 14 February) begins, new figures highlight the growing importance of industry-academic partnerships in filling skills gaps, advancing research, and keeping the UK ahead in global life sciences innovation.
ABPI comment on 2025 VPAG rates of 22.9%
The Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) payment rate for newer medicines has been set at 22.9% in 2025, well above expectations, putting UK industry growth and investment at risk.
Life sciences growth requires payment rates to return to internationally comparable levels
Existing and proposed medicine payment rates of a quarter to a third of UK pharmaceutical company revenue are incompatible with government ambitions to grow the sector.
ABPI welcomes announcement of ten-year budgets for R&D funding
The Department for Science, Innovation and Technology (DSIT) today announced new ten-year budgets for science funding.
BioNTech’s investment provides a template for UK growth, say ABPI
The innovative biopharmaceutical company BioNTech has announced a major investment of up to £1bn over 10 years in the UK, potentially creating more than 400 new jobs in London and Cambridge.
Spending Review – NHS must invest more in proven innovations, says ABPI
The government spending review has concluded with a 3% per year increase for health and the NHS. As part of fixing the broken NHS, the innovative pharmaceutical industry is calling for greater focus to be put on investing in those areas of health spending that have the strongest evidence for both value for money and for directly improving patient outcomes.
Coalition calls for roadmap to improve inclusivity in clinical research
Encouraging participation of a wide range of diverse communities in clinical research is essential to make sure that innovative medicines meet the needs of the people they are intended for, says a new report from ABPI and AMRC.
ABPI response to the new Industrial Strategy
The government’s new Industrial Strategy reaffirms its commitment to growing the economy. The key test for life sciences will be whether it can return the UK to international competitiveness.
ABPI response to NHS 10-Year Health Plan
The NHS 10-Year Health Plan gets it right on genomics and advanced therapies, as well as accelerated clinical trials and supporting participation in research. However, innovative medicines could play a far greater role in revolutionising healthcare. The plan also sends a worrying signal about limiting patient and doctor choices around the best treatment for
UK life sciences plan falls short, says ABPI
The ABPI is warning that the core ambition of the government's new life sciences strategy will not be realised unless it makes a real commitment to invest more in new medicines.
Laura McMullin of Daiichi Sankyo named as new ABPI Vice-President
The ABPI has appointed Laura McMullin as Vice-President of the ABPI.
Attracting global talent is key to UK Life Sciences success
If the UK is to become Europe’s leading life sciences economy by 2030, it must sharpen its global appeal and do more to attract and keep world-class talent.
Accelerated review of VPAG concludes without agreement
The ABPI can confirm that industry and government have been unable to reach an agreement on changes to a controversial medicines payment scheme which is undermining UK patient access to innovative medicines and the competitiveness of the UK life sciences industry.